Genta's stock is depressed
Genta closed Thursday at $12.34 per share. The stock has lost 33% since hitting its 52-week high of $18.49 on March 22, despite news on Monday that it inked a Genasense
Trevena intends to submit the new painkiller, known as oliceridine, for marketing approval with the U.S. Food and Drug Administration in the fourth quarter, the company said.
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.